Canagliflozin
Back to searchMolecule Structure
Scientific Name
Canagliflozin
Description of the Drug
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08907
http://www.drugbank.ca/drugs/DB08907
Brand Name(s)
Not Available
Company Owner(s)
Janssen Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL3884 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL157162 | ||
| DrugBank | DB08907 | ||
| PubChem: Thomson Pharma | 49811874 | ||
| PubChem | 24812758 | ||
| LINCS | LSM-45965 | ||
| Nikkaji | J2.830.773J | ||
| BindingDB | 50386885 | ||
| DrugCentral | 4758 | ||
| Guide to Pharmacology | 4582 | ||
| rxnorm | CANAGLIFLOZIN | INVOKANA | CANAGLIFLOZIN ANHYDROUS |
| PubChem: Drugs of the Future | 125299338 | ||
| ChEBI | 73274 | ||
| ZINC | ZINC000043207238 |
